Citation Report

List of articles citing

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs

DOI: 10.1016/s0959-8049(03)00235-1
European Journal of Cancer, 2003, 39, 1348-54.

Source: https://exaly.com/paper-pdf/35545062/citation-report.pdf
Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
205	Getting to grips with gefitinib. **2003**, 4, 719-20		1
204	Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. **2004**, 10, 4607-13		56
203	Strategies for multiple signalling inhibition. **2004**, 16 Suppl 4, 41-3		15
202	Searching for reliable epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res., 10: 691-700, 2004. **2004**, 10, 428-32		16
201	Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. **2004**, 22, 4772-8		212
200	Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. **2004**, 10, 3069-75		168
199	Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. **2004**, 91, 208-12		180
198	Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. **2004**, 58, 970-6		27
197	. **2004**, 24, 35-52		44
196	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. **2004**, 351, 337-45		4112
195	Bibliography. Current world literature. Breast. **2004**, 16, 621-54		
194	Bibliography Current World Literature. **2004**, 16, 238-279		
193	The role of EGFR inhibitors in nonsmall cell lung cancer. **2004**, 16, 130-5		76
192	Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. **2005**, 24, 147-52		53
191	c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. **2005**, 31, 263-74		52
190	Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. **2005**, 18, 1350-6		125
189	Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. **2005**, 32, S59-62		27

188	N-methyl-N'-nitro-N-nitrosoguanidine interferes with the epidermal growth factor receptor-mediated signaling pathway. **2005**, 570, 175-84		15
187	Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?. **2005**, 390, 94-103		75
186	Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. **2006**, 62, 1026-35		56
185	Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. **2005**, 68, 500-10		17
184	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. **2005**, 6, 279-86		833
183	Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. **2005**, 288, G447-56		109
182	Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. **2005**, 8, 15-26		111
181	Mechanisms of drug resistance in cancer chemotherapy. **2005**, 14 Suppl 1, 35-48		411
180	Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer. **2006**, 7, 73-86		15
179	Recent developments in the systemic therapy of advanced gastroesophageal malignancies. **2006**, 15, 131-53		6
178	Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. **2006**, 66, 1441-63		11
177	New insights into the molecular pathogenesis of colorectal cancer. **2006**, 3, 439		6
176	Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. **2006**, 12, 5064-73		402
175	Key cancer cell signal transduction pathways as therapeutic targets. *European Journal of Cancer*, **2006**, 42, 290-4	7.5	118
174	EPIDERMAL GROWTH FACTORS. **2006**, 129-133		3
173	Transforming growth factor alpha acts as a gliatrophin for mouse and human astrocytes. **2006**, 25, 4076-85		24
172	Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. **2006**, 13, 823-35		93
171	Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells. **2006**, 71, 1265-71		19

170	Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. **2006**, 106, 1857-62	31
169	Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. **2006**, 12, 577-83	75
168	Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. **2006**, 66, 7708-15	34
167	Improved mutants from directed evolution are biased to orthologous substitutions. **2006**, 19, 245-53	53
166	EGFR Inhibitors and Radiation in HNSCC. **2007**, 3, 255-266	
165	Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. **2007**, 25, 3007-14	65
164	Membrane-type 1 matrix metalloproteinase stimulates cell migration through epidermal growth factor receptor transactivation. **2007**, 5, 569-83	26
163	Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. **2007**, 2, 758-61	31
162	Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. **2007**, 26, 235-41	21
161	Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. **2007**, 15, 305-9	16
160	Epidermal growth factor receptor distribution in pericoronal follicles: relationship with the origin of odontogenic cysts and tumors. **2007**, 103, 240-5	25
159	Current stumbling blocks in oncology drug development. **2007**, 135-49	2
158	Current role of antibody therapy in patients with metastatic colorectal cancer. **2007**, 26, 3661-78	44
157	Quantitative analysis of argyrophilic nucleolar organizer regions and epidermal growth factor receptor in ameloblastomas. **2007**, 36, 99-104	7
156	Expression of epidermal growth factor receptor (EGFR) is frequent in inflammatory bowel disease (IBD)-associated intestinal cancer. **2007**, 450, 243-4	17
155	Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. **2008**, 66, 155-62	38
154	Synthesis and characterization of novel quinazoline type inhibitors for mutant and wild-type EGFR and RICK kinases. **2008**, 28, 361-73	6
153	Absence of epidermal growth factor receptor mutations in cervical cancer. **2008**, 18, 749-54	30

152	Developing therapeutic proteins by engineering ligand-receptor interactions. **2008**, 26, 498-505	32
151	Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines. **2008**, 54, 463-74	25
150	EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. **2008**, 8, 417-34	76
149	Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. **2008**, 6, 53-63	25
148	Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome. **2008**, 4, 413-25	4
147	Long-lasting control with erlotinib in advanced non-small cell lung cancer (NSCLC). **2008**, 14 Suppl 3, S9-S15	0
146	Transient receptor potential type vanilloid 1 suppresses skin carcinogenesis. **2009**, 69, 905-13	78
145	Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. **2009**, 125, 1390-7	39
144	Novel chemotherapy approaches for cervical cancer. **2009**, 115, 3166-80	64
143	T1 N0 triple negative breast cancer: a bad actor. **2009**, 15, 451-3	
142	Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma. **2009**, 279, 30-8	40
141	Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. **2009**, 87, 432-7	54
140	Toxicity of targeted therapy in non-small-cell lung cancer management. **2009**, 10, 28-35	70
139	A kernel-based integration of genome-wide data for clinical decision support. **2009**, 1, 39	54
138	Should we be surprised at the paucity of response to EGFR inhibitors?. **2009**, 10, 522-7	42
137	Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis. **2010**, 3, 1493-502	20
136	Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. **2010**, 102, 165-72	69
135	Effect and risk of AEE788, a dual tyrosine kinase inhibitor, on regeneration in a rat liver resection model. **2010**, 44, 82-95	5

134	Mechanisms underlying resistance to cetuximab in the HNSCC cell line: Role of AKT inhibition in bypassing this resistance. **2010**, 38,		6
133	New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. **2010**, 16, 2489-95		89
132	EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas. *European Journal of Cancer*, **2011**, 47, 2364-72	7.5	23
131	Selective growth inhibition of human breast cancer cells by graviola fruit extract in vitro and in vivo involving downregulation of EGFR expression. **2011**, 63, 795-801		59
130	Possible role of epidermal growth factor receptors in the therapy of pancreatic cancer. **2011**, 28, 293-356		5
129	Epidermal Growth Factor Receptor (EGFR) Phosphorylation, Signaling and Trafficking in Prostate Cancer. **2011**,		4
128	Role of molecular markers in the management of head and neck cancers. **2011**, 23, 259-64		22
127	Genetics/epigenetics of oral premalignancy: current status and future research. **2011**, 17 Suppl 1, 7-22		82
126	A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). **2011**, 67, 465-74		28
125	Reply to D. Herchenhorn et al. **2011**, 29, e285-e287		3
124	A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling. **2011**, 300, F393-402		17
123	Control of solid tumor growth in mice using EGF receptor-targeted RNA replicase-based plasmid DNA. **2012**, 7, 475-91		4
122	Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas. **2012**, 61, 644-51		1
121	Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer. **2012**, 136, 89-105		4
120	Novel targeted therapies in head and neck cancer. **2012**, 21, 281-95		9
119	Zeolite Structures Loading with an Anticancer Compound As Drug Delivery Systems. **2012**, 116, 25642-25650		100
118	High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. **2012**, 43, 1590-5		51
117	PIKE mediates EGFR proliferative signaling in squamous cell carcinoma cells. **2012**, 31, 5090-8		12

116	Multifunctional Nanoparticles for Drug Delivery Applications. **2012**,	25
115	Polymer-Modified Nanoparticles as Targeted MR Imaging Agents. **2012**, 173-198	1
114	Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture. **2012**, 18, 1313-22	32
113	Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer. **2012**, 2012, 986725	21
112	High-expression EGFR/cell membrane chromatography-online-high-performance liquid chromatography/mass spectrometry: rapid screening of EGFR antagonists from Semen Strychni. **2012**, 26, 2027-32	22
111	Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine(R15) triblock copolymer for siRNA delivery. **2012**, 33, 6793-807	107
110	EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. **2012**, 157, 287-96	49
109	Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. **2013**, 34, 8690-707	323
108	Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases. **2013**, 28, 555-62	5
107	Potentiation of 5-fluorouracil encapsulated in zeolites as drug delivery systems for in vitro models of colorectal carcinoma. **2013**, 112, 237-44	76
106	A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. **2013**, 49, 461-7	76
105	HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer. **2013**, 19, 206-11	17
104	Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. **2013**, 59, 252-60	192
103	Impact of epidermal growth factor receptor, mesenchymal-epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancer. **2013**, 51, 234-40	13
102	Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma. **2013**, 445, 79-87	65
101	Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. **2013**, 30, 447-55	10
100	Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. **2013**, 35, 1323-30	20
99	Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model. **2013**, 34, 1427-36	11

98	Mechanisms of resistance to EGFR targeted therapies. **2013**, 14, 304-14	41
97	Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts. **2013**, 29, 260-8	20
96	Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications. **2014**, 271, 211-23	24
95	Is biomarker research advancing in the era of personalized medicine for head and neck cancer?. **2014**, 19, 211-9	17
94	Over-expression of EGFR is closely correlated to poor prognosis in Tunisian patients with non-small cell lung adenocarcinoma. **2014**, 35, 256-68	9
93	Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC). **2014**, 19, 198-206	16
92	Slow release of ions from internalized silver nanoparticles modifies the epidermal growth factor signaling response. **2014**, 123, 136-42	36
91	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. **2015**, 13, 217	30
90	An improved cell membrane chromatography method for the simultaneous screening of two epidermal growth factor receptor antagonists from radix scutellariae. **2015**, 38, 3145-3150	10
89	Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics. **2015**, 10, e0119765	13
88	Lead compound bearing caffeic scaffold induces EGFR suppression in solid tumor cancer cells. **2015** , 13, 305-317	2
87	Differential Effects of Tumor Secreted Factors on Mechanosensitivity, Capillary Branching, and Drug Responsiveness in PEG Hydrogels. **2015**, 43, 2279-90	4
86	Epigenetic regulation of protein tyrosine phosphatase PTPN12 in triple-negative breast cancer. **2015**, 130, 73-80	11
85	Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. **2016**, 38, 1759-1764	42
84	Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients. **2016**, 12, 2127-2132	11
83	Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study. **2016**, 27, 533-9	4
82	Lapatinib-induced mesenchymal-epithelial transition in squamous cell carcinoma cells correlates with unexpected alteration of Ecatenin expression. **2016**, 11, 2715-2724	5
81	Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo. **2016**, 33, 2388-99	17

80	Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck. **2016**, 155, 106-12	6
79	Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patients. **2016**, 11, 173-181	5
78	Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. **2016**, 24, 301-309	10
77	ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth. **2016**, 35, 1554-64	10
76	MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray. **2017**, 70, 533-540	22
75	Photonic modulation of EGFR: 280nm low level light arrests cancer cell activation and migration. **2017**,	
74	Peptide-Au Cluster Probe: Precisely Detecting Epidermal Growth Factor Receptor of Three Tumor Cell Lines at a Single-Cell Level. **2017**, 2, 276-282	10
73	Serum Quantitative Proteomic Analysis Reveals Soluble EGFR To Be a Marker of Insulin Resistance in Male Mice and Humans. **2017**, 158, 4152-4164	5
72	Ultrasmall Paramagnetic Iron Oxide Nanoprobe Targeting Epidermal Growth Factor Receptor for In Vivo Magnetic Resonance Imaging of Hepatocellular Carcinoma. **2017**, 28, 2794-2803	8
71	Genetically functionalized ferritin nanoparticles with a high-affinity protein binder for immunoassay and imaging. **2017**, 988, 81-88	11
70	Bimodal fluorescence/Xe NMR probe for molecular imaging and biological inhibition of EGFR in Non-Small Cell Lung Cancer. **2017**, 25, 6653-6660	9
69	Targeting cancer cell integrins using gold nanorods in photothermal therapy inhibits migration through affecting cytoskeletal proteins. **2017**, 114, E5655-E5663	121
68	Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors. **2017**, 25, 4553-4559	7
67	Targeted delivery of anticancer drugs: new trends in lipid nanocarriers. **2017**, 455-484	2
66	Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma. **2017**, 22, 181-189	9
65	Electrostatically assembled dendrimer complex with a high-affinity protein binder for targeted gene delivery. **2018**, 544, 39-45	12
64	A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification. **2018**, 10, 5328-5338	11
63	Synthesis of Triazole-Substituted Quinazoline Hybrids for Anticancer Activity and a Lead Compound as the EGFR Blocker and ROS Inducer Agent. **2018**, 3, 16134-16142	23

62	Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC. **2018**, 26, 6135-6145	9
61	WNT and NOTCH signaling pathways as activators for epidermal growth factor receptor in esophageal squamous cell carcinoma. **2018**, 23, 42	25
60	Prognostic impact of combined immunoprofiles in oropharyngeal squamous cell carcinoma patients with respect to AJCC 8th edition. **2018**, 47, 864-872	3
59	Matrix Stiffening and EGFR Cooperate to Promote the Collective Invasion of Cancer Cells. **2018**, 78, 5229-5242	43
58	Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters. **2019**, 11,	34
57	Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. **2019**, 8, 54	7
56	Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo. **2019**, 91, 258-269	4
55	Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?. **2019**, 11,	22
54	Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. **2019**, 79, 633-645	22
53	Analyses of the possible anti-tumor effect of yokukansan. **2019**, 73, 468-479	3
52	An Overview of Recent Advances in the Applications of Click Chemistry in the Synthesis of Bioconjugates with Anticancer Activities. **2019**, 4, 13459-13478	19
51	Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer. **2020**, 77, 997-1019	21
50	HS2ST1-dependent signaling pathways determine breast cancer cell viability, matrix interactions, and invasive behavior. **2020**, 111, 2907-2922	11
49	Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of Lu-Nimotuzumab. **2020**, 96, 1144-1156	2
48	Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. **2020**, 30, 1733-1737	0
47	Perspectives on liquid biopsy for label-free detection of □circulating tumor cells□through intelligent lab-on-chips. **2020**, 1, 20200034	32
46	Synthesis, anti-cancer evaluation and molecular docking studies of aryl bisindole derivatives. **2020**, 29, 100511	
45	Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. **2020**, 39, 112	74

44	Current Perspectives on Zr-PET Imaging. **2020**, 21,	23
43	CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients' plasma as potential noninvasive biomarkers of disease activity. **2020**, 9, 1747732	23
42	Down-regulation of USP8 Inhibits Cholangiocarcinoma Cell Proliferation and Invasion. **2020**, 12, 2185-2194	6
41	Cucurbitacin IIb induces apoptosis and cell cycle arrest through regulating EGFR/MAPK pathway. **2021**, 81, 103542	8
40	Advances and challenges in the treatment of esophageal cancer.. **2021**, 11, 3379-3392	14
39	Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress. **2021**, 13,	5
38	Semisynthetic Triazoles as an Approach in the Discovery of Novel Lead Compounds. **2021**, 25, 1097-1179	
37	The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients. **2021**, 10,	4
36	Nanomedicines functionalized with anti-EGFR ligands for active targeting in cancer therapy: Biological strategy, design and quality control. **2021**, 605, 120795	7
35	Intracholecystic papillary neoplasm of the gallbladder diagnosed during follow-up of Menetrier's disease: A case report. **2021**, 15, 233	1
34	Synthesis, crystallography, DFT, MTT assay, and molecular docking studies of an exocyclic double-bonded crystalline chalcone. **2021**, 36, 100773	1
33	Role of Tumour Microenvironment in Chemoresistance. **2005**, 285-321	7
32	Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. **2005**, 63, 93-114	9
31	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. **2017**, 2, e90449	30
30	Targeting Anti-Cancer Active Compounds: Affinity-Based Chromatographic Assays. **2016**, 22, 5976-5987	19
29	Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers. **2008**, 14, 1053-9	10
28	Molecular docking based screening of novel designed chalcone series of compounds for their anti-cancer activity targeting EGFR kinase domain. **2015**, 11, 322-9	19
27	Expression of EGFR and p53 in head and neck tumors among Sudanese patients. **2013**, 14, 6415-8	15

26	Pharmacogenetics in Oncology. **2006**, 129-153	
25	Head and Neck Tumours. **2012**, 19-59	
24	Current Research into Head and Neck Cancer Molecular Targeted Therapy and Human Papilloma Virus Infection in Head and Neck Squamous Cell Carcinoma. **2012**, 105, 183-191	
23	Unraveling the role of epidermal growth factor receptor in oral lesions: Key to non surgical treatment modes. **2015**, 4, 22	
22	Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). **2018**, 365-396	
21	Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials. **2020**, 5, 1056-1062	
20	C-demethylation and 1, 2-amino shift in (E)-2-(1-(3-aminophenyl) ethylidene)hydrazinecarboxamide to (E)-2-(2-aminobenzylidene)hydrazinecarboxamide and their applications. **2020**, 10, 21913	
19	How to Define Treatment Success or Failure if Tumors Do Not Shrink. **2008**, 657-674	
18	Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. **2009**, 2, 249-60	43
17	High-sensitivity epidermal growth factor receptor immunostaining for colorectal carcinomas, compared with EGFR PharmDx□a study of diagnostic accuracy. **2013**, 6, 24-30	4
16	[MicroRNA and lung cancer]. **2010**, 13, 380-5	1
15	Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer. **2020**, 21, 3153-3163	1
14	A novel prognostic target-gene signature and nomogram based on an integrated bioinformatics analysis in hepatocellular carcinoma. **2022**, 46, 1261-1288	1
13	Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer. **2020**, 21, 3153-3163	1
12	Combinatorial Cetuximab targeted polymeric nanocomplexes reduce PRC1 level and abrogate growth of metastatic hepatocellular carcinoma in vivo with efficient radionuclide uptake.. **2022**, 102529	0
11	Design, Synthesis and Biological Evaluation of Novel Indole-Containing Sorafenib Derivatives. **2022**, 104, 667	
10	Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption.. **2022**, 283, 121416	0
9	Ramachary-Bressy-Wang [3+2]cycloaddition reaction: Synthesis of fully decorated 1,2,3-triazoles as potent anticancer and EGFR inhibitors. **2022**, 132975	4

8	A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.. **2022**, 29, 1243-1256	0
7	Multimodal targeting of glioma with functionalized nanoparticles. **2022**, 22,	0
6	Identification of EGFR as a Biomarker in Saliva and Buccal Cells from Oral Submucous Fibrosis PatientsA Baseline Study. **2022**, 12, 1935	0
5	Exosomes at the crossroad between therapeutic targets and therapy resistance in head and neck squamous cell carcinoma. **2022**, 188784	0
4	Effect of cholesterol-lowering agents on soluble epidermal growth factor receptor level in type 2 diabetes and hypercholesterolemia. **2022**, 101, e30287	0
3	An ultra-performance LCMS/MS method for determination of JRF103 in human plasma: application in first-in-patient study.	0
2	Synthesis and biological evaluation of novel [1,2,3]triazolo-pyrrolo[1,2-a]pyrido[4,3-d]pyrimidines as EGFR targeting anticancer agents. **2023**, 1274, 134378	1
1	The mechanism of flavonoids from Cyclocarya paliurus on inhibiting liver cancer based on in vitro experiments and network pharmacology. 14,	0